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Abstract
Introduction: The article focuses on the early manifestations of adverse side effects in children with nephrotic syn­
drome receiving glucocorticosteroids. The search for criteria of early side effect manifestations is a real challenge 
nowadays. The authors developed new diagnostic criteria for early detection of pharmacotherapeutical side effects in 
children with nephrotic syndrome.
Objective: The aim of the study was to develop integral quantitative diagnostic criteria for early detection of side ef­
fects of glucocorticosteroids when treating nephrotic syndrome in children.
Materials and Methods: The study included 58 in-patients, aged 1-18. All the children had been thoroughly examined 
and their parameters had been investigated: height and body mass by calculating Z-scores (WHO ANTHRO Plus) and 
body mass index (BMI), a biochemical blood test, a full blood count by studying the total number of leukocytes, the 
percentage of neutrophils and monocytes in peripheral blood, systolic and diastolic blood pressure.
Results and Discussion: The parameters that changed in the patients with nephrotic syndrome taking corticosteroids 
are referred to as diagnostic criteria. They included leukocytes, neutrophils and monocytes parameters in the full blood 
count, blood glucose and amylase level, patients’ body mass, BMI, systolic and diastolic arterial pressure. The authors 
defined the change range of the parameters under study in the children with nephrotic syndrome based on the obtained 
findings.
Conclusion: The authors conclude that application of the developed indices will make it possible to diagnose early 
metabolic, cardio-vascular and immunologic changes in patients with nephrotic syndrome taking glucocorticoids and 
perform their individual pharmacological correction in a timely manner.
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Introduction
The pharmacotherapy applied in treating most diseases 
is characterised not only by the efficiency of arresting di-
verse pathologies, but also by developing various adverse 
side effects (Cliff-Eribo 2016). The more active the drug 
is in interfering with various pathological body processes, 
the more serious are the caused side effects. Looking for
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early criteria of side effect development is considered to 
be a real challenge nowadays. The authors investigated 
new diagnostic criteria for early detection of pharmaco- 
therapeutical side effects in children with nephrotic syn­
drome.
High doses of glucocorticosteroids which make re­
mission possible in most patients are used in treating ne­
phrotic syndrome in children (Ministry of Healthcare of 
the Russian Federation 2018, KDIGO 2012). A prolonged 
corticosteroid therapy can lead to the development of ad­
verse side effects such as arterial hypertension, Cushing’s 
syndrome, glucose intolerance, osteoporosis, gastro-in- 
testinal disorders, leukemoid reactions, increased sus­
ceptibility to infectious diseases etc. (Landyshev 2014, 
Aljebab et al. 2017). Side effects of glucocorticosteroid 
therapy depend on both a treatment dose and its duration 
and on a patient’s individual susceptibility. They are clas­
sified depending on the hormone impact on various body 
systems -  the central nervous system, endocrine system, 
cardio-vascular system, the gastro-intestinal tract, immu­
nity etc. (Strachunsky and Kozlov 2018). A great num­
ber of researchers have assessed the influence of various 
schemes of glucocorticosteroid therapy on the risk of de­
veloping nephrotic syndrome recurrence in children and 
the frequency of therapeutical side effects; however, no 
early diagnostic on adverse side effects which would of­
fer the possibility to correct the administered therapy in 
a timely manner has ever been performed (Hjorten et al. 
2016, Obuhkova and Dlin 2014).
Objective: This study was aimed at developing inte­
gral quantitative diagnostic criteria for early detection of 
side effects of glucocorticosteroids administered in the 
therapy of nephrotic syndrome in children.
Materials and Methods
In 2012-2014, 58 in-patients were examined with 
nephrotic syndrome, aged 1-18, receiving treatment 
at Voronezh Regional Clinical Paediatric Hospital № 
1. The height and body mass with calculation of the 
body mass index (BMI) according to the formula had 
been measured in all the children. Z-scores (WHO 
ANTHRO Plus) and BMI reference ranges were cal­
culated in the children from birth to 5 years and from 
5 to 19 years (WHO 2018). A biochemical blood test 
was undertaken by studying the glucose and amylase 
level in blood serum, as well as a full blood count by 
examining the total number of leukocytes, the percen­
tage of neutrophils and monocytes in peripheral blood. 
All forms of neutrophil leukocytes detected in child­
ren (metamyelocytes, myelocytes, immature, stab, 
segmented neutrophils) were taken into consideration 
when calculating a neutrophil percentage.
The children with nephrotic syndrome received a pro­
longed therapy with high doses of corticosteroids (Hahn 
et al. 2015, Lombel et al. 2013). Metabolic and clinical 
parameters in the patients were measured repeatedly at
various stages of the disease: at the onset or relapse stage, 
prior to corticosteroid administration, weekly during 
their administration, during remission and after the drug 
withdrawal. Amongst the patients under study, there were 
children with adverse reactions when treated with corti­
costeroids.
The priority of the suggested methods was recognised 
by the patents granted by the Russian Federation (Russian 
Federation Patent 2 633 591(13) 2017, Russian Federa­
tion Patent 2 633 592(13) 2017).
All stages of the study were consistent with legislation 
of the Russian Federation, international ethical standards 
and approved by the Ethics Committee of Voronezh State 
Medical Academy named after N.N. Burdenko.w
Results and Discussion
As a result of the studies conducted, methods were propo­
sed for early detection of side effects of corticosteroids to 
various types of metabolism and leukocytes of peripheral 
blood in children with nephrotic syndrome, so that timely 
pharmacological correction of adverse side effects of cor­
ticosteroids could be performed.
To develop diagnostic criteria, the parameters that 
changed in patients with nephrotic syndrome during 
corticosteroid therapy were selected. They included leu­
kocytes, neutrophils and monocytes parameters in the 
full blood count, blood glucose and amylase level, pa­
tients’ body mass, systolic and diastolic arterial pressure 
findings. The measurement of the changeable parame­
ters in the patients was carried out repeatedly at various 
stage of the disease: at the onset or relapse stage, prior 
to corticosteroid administration, weekly during their ad­
ministration, during remission and after drug withdraw­
al. The change range of the parameters under study in 
the children with nephrotic syndrome was determined 
based on the obtained findings. The comparison group 
included 120 healthy children and adolescents, whose 
parameters under study were also measured. Table 1 
contains the example of the obtained change range of 
the parameters in the healthy children and in the pa­
tients with nephrotic syndrome.
A modification coefficient was calculated for each of 
the defined parameters according to formula (1):
М  = 30 x _ _  (1),
where M -  a modification coefficient of each parameter,
Ai -  a value of one of the parameters to study,
Amax and Amin -change limits of the parameters in 
healthy people and in patients with nephrotic syndrome 
(Table 1).
With the help of formula (1), the parameters under 
study are brought to the unified scale from 1 to 30, which 
makes it possible to differentially assess and compare the 
deviation scope of the studied values.
The values of segmented neutrophils (Segs), systolic 
arterial pressure (SAP), diastolic arterial pressure (DAP)
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Table 1. Change Range of Parameters Under Study in Healthy Children and in Patients with Nephrotic Syndrome
Patients with nephrotic syndrome
No adverse drug side effects Adverse drug effect to Values of the parameters
Parameters
Healthy children to corticosteroids corticosteroids under study
Min* Max* Min* Max* Min* Max* Amin** Amax**
Leukocytes, •109/l 4.0 10.3 3.5 10.5 11.0 31.5 3.5 31.5
Neutrophils, % 21 63 19 62 44 84 19 84
Monocytes, % 2 8 3 7 7 17 2 17
Note: * -  minimum and maximum values of the studied parameters obtained when examining children and patients with nephrotic 
syndrome; ** - change range of the studied parameters.
and heart rate (HR) obtained in the patients were ex­
pressed in deviation percent of the mean value of the age 
norm using formula (2):
Ai (%) = _ _  (2),
where Ai -  a value of one of the investigated parameters, 
Apat -  a value of the investigated parameter in a patient, 
Amean -  a mean value for a child of a given age and 
gender.
Diagnostic indices -  index of metabolic reactions 
(IMR) by formula (3), index of immunological reactions 
(IIR) by formula (4), index of cardio-vascular reactions 
(ICR) by formula (5) -  were calculated by applying the 
modification coefficient.
IMR Mbmi + Mgl + Mam3
where IMR -  index of metabolic reactions, 
Mbmi -  a modification coefficient of BMI, 
Mgl -  a modification coefficient of glucose, 
Mam -  a modification coefficient of amylase.
Mleu + Mstab + Msegm + Mmon
(3),
(4),
where IIR -  index of immunological reaction,
Mleu -  a modification coefficient of leukocytes,
Mstab -  a modification coefficient of stab neutrophils, 
Msegm -  a modification coefficient of segmented neu­
trophils,
Mmon -  a modification coefficient of monocytes.
ICR Msyst + Mdiast + Mhr3 (5),
where ICR -  index of cardio-vascular reactions,
Msyst -  a modification coefficient of systolic blood 
pressure,
Mdiast -  a modification coefficient of diastolic blood 
pressure,
Mhr -  a modification coefficient of the heart rate.
Reference index values -  IIR <12 units, IMR < 14.5, 
ICR < 14 units - were developed on the basis of the per­
formed studies of the test parameters in the healthy child­
ren. If the patient’s indices are within these ranges, no 
pharmacological correction for the adverse side effects of 
glucocorticosteroids is necessary.
A boy X, aged 6, was examined during a regular check­
up prior to school admission. His diagnosis was: healthy. 
The results of this examination are shown in Table 2 to­
gether with the calculated indices.
The calculated integral indices (Table 2) when exami­
ning the boy, were IMR -  8.0 units (IMR < 14.5), IIR 
-  5.6 units (IIR <12), ICR -  9.0 units (ICR < 14), which 
proved the conclusion about his adequate state of health.
A boy Z, aged 7, was diagnosed with nephrotic syn­
drome, steroid-sensitive variant. He had been ill for two 
months, now in a remission period. He had a safe kidney 
function. He had received a glucocorticoid (prednisolone) 
therapy, dose 60 mg/m2 of his body surface, for 6 weeks. 
The boy was examined before transfer to the alternating 
treatment period.
The results of this examination are given in Table 3 
together with the calculated indices.
The calculated integral indices (Table 3) when exami­
ning the boy Z, were IMR -  16.1 units (IMR > 14.5), 
IIR -  14.8 units (IIR > 12), ICR -  9.5 units (ICR < 14), 
which testified to the adverse side effects of glucocorti­
coids on the metabolism and leukogram and demanded 
administration of pharmacological correction and dyna­
mic control of the above-mentioned parameters during 
the ongoing corticosteroid therapy.
Conclusions
Assessment of the influence of various schemes of corti­
costeroid therapy on the development of nephrotic syn­
drome relapses in children and frequency of detection of 
adverse side effects is highlighted in the Cochrane review 
(Hahn et al. 2015). However, adverse reactions in the stu­
dies included in this review were assessed only regarding 
various therapeutical schemes; there have been no speci­
fic studies to examine side effects of corticosteroid thera­
py in children with nephrotic syndrome (Ishikura 2015). 
There has been no specification of various groups of ad­
verse effects depending on the impact of corticosteroids 
on various body systems.
There are some recommendations known nowadays 
on monitoring children with nephrotic syndrome recei­
ving corticosteroid therapy (Lombel et al. 2013). They 
include a list of necessary clinic, laboratory and instru­
mental parameters and their test frequency. However, no 
specific groups of parameters indicating the influence of 
corticosteroids on various body systems (metabolic, im­
munologic and others) are identified; neither are there all 
the metabolic parameters that can change when taking
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Table 2. Examination Results of Boy X
Group of findings Parameters*
Modification coefficients of 
the parameters** Integral indices***
Metabolic findings Height -  120 cm, 
Body mass -  22 kg, 
BMI -  15.3 
z-score BMI = -0.15
Mbmi = 13.2 IMR = 8.0
Glucose = 4.2 mmol/L Mgluc = 5.7
Amylase = 42 mg% Mam = 5.1
Full blood test findings leukocytes = 4.7-109/л Mleuk = 2.9 3 II L/i b\
Stab neutroph. = 1 % Mstab = 2.0
Segm. neutroph. -  44%
Segm. neutroph. = 47.3% of the norm
Msegm = 13.8
Monocytes = 5% Mmon = 3.9
Cardio-vascular system Syst. BP -  95 mm Hg.
Syst. BP = 46.6% of the norm
Msyst. = 8.6 ICR = 9.0
Diast. BP -  65 mm Hg Mdias. = 9.7
Diast. = 49.2% of the norm
HR -  90 beat per min Mhh = 8.6
HR = 46.4% of the norm
Note: * -  BMI -  body mass index, z-score -  body mass calculated in WHO ANTHRO Plus, stab neutroph. -  stab neutrophils, segm. 
neutroph. -  segmented neutrophils, syst. BP -  systolic blood pressure, diast. BP -  diastolic blood pressure, HR -  heart rate;
** -  Mbmi, Mgluc, Mam, Mleuk, Mstab, Msegm, Mmon, Msyst, Mdias, Mhr -  modification coefficients of body mass index, glu­
cose, amylase, leukocytes, stab neutrophils, segmented neutrophils, monocytes, systolic blood pressure, diastolic blood pressure, 
heart rate respectively;
*** -  IMR -  index of metabolic reactions, IIR -  index of immunological reactions, ICR -  index of cardio-vascular reactions.
Table 3. Examination Results of Boy Z
Modification coefficients of
Group of findings Parameters* the parameters ** Integral indices***
Metabolic findings Height - 129 cm, 
Body mass -  35 kg, 
BMI -  21.0 
z-score BMI = 2.48
Mbmi = 20.4 IMR = 16.1
Glucose = 5.2 mmol/L Mgluc = 9.3
Amylase = 128 mg% Mam = 18,6
Full blood test findings Leukocytes = 22d09/l Mleuk = 21.4 IIR = 14.8
Stab neutroph. = 2 % Mstab = 4.6
Segm. neutroph. -  62% 
Segm. neutroph. = 63.5% 
of the norm
Msegm = 20.1
Monocytes = 12% Mmon = 13.0
Cardio-vascular system Syst. BP -  100 mm Hg 
Syst. BP = 48% of the norm
Msyst = 9.1 ICR = 9.5
Diast. BP -  60 mm Hg Mdiast = 7.8
Diast. BP = 45% of the norm
HR -  100 beats per min Mhh = 11.5
HR = 54% of the norm
Note: * -  BMI -  body mass index, z-score -  body mass calculated in WHO ANTHRO Plus, stab neutroph. -  stab neutrophils, segm. 
neutroph. -  segmented neutrophils, syst. BP -  systolic blood pressure, diast. BP -  diastolic blood pressure, HR -  heart rate;
** -  Mbmi, Mgluc, Mam, Mleuk, Mstab, Msegm, Mmon, Msyst, Mdias, Mhr -  modification coefficients of body mass index, glu­
cose, amylase, leukocytes, stab neutrophils, segmented neutrophils, monocytes, systolic blood pressure, diastolic blood pressure, 
heart rate respectively;
*** -  IMR -  index of metabolic reactions, IIR -  index of immunological reactions, ICR -  index of cardio-vascular reactions.
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corticosteroids (blood glucose); no parameters are menti­
oned that can act as early markers of adverse side effects 
of corticosteroids.
Sporadic metabolic side effects of corticosteroids in 
children with nephrotic syndrome are described in litera­
ture, for example, pancreatoxicity, obesity (Bekmurzaye- 
va et al. 2012, Foster et al. 2006). However, no criteria for 
early detection of pancreatic damage during the corticos­
teroid therapy are given.
When taking glucocorticoids for a long period of time, 
some changes may occur in the full blood test parameters 
which are well known, i.e. a decrease in the number of 
lymphocytes, eosinophils, basophils with simultaneous 
development of neutrophil leukocytosis, persisting for 
1-4 weeks (Landyshev 2014). The recommendations on 
monitoring children with nephrotic syndrome receiving 
glucocorticoid therapy include a demand to control full
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